ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASSEMBLY BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.16+0.07 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $380.09M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
92.1%
19M of 20M shares
Institutional holders
93
34 new, 15 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 5 sales
Net sold $14.69K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Paradigm BioCapital Advisors GP LLC | 865,251 | 5.40% | 13G (passive) | May 4, 2026 |
| Gilead Sciences, Inc. | 4,977,089 | 25.10% | 13D (active) amendment | May 22, 2026 |
| Commodore Capital LP | 1,615,981 | 9.90% | 13G (passive) | Aug 8, 2025 |
| Saito Edric C. | 1,604,590 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Senai Asefaw, M.D. | 1,553,748 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky | 1,530,615 | 9.50% | 13G (passive) | Aug 11, 2025 |
| JANUS HENDERSON GROUP Ltd. | 1,359,514 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Janus Henderson Group PLC | 1,341,508 | 8.20% | 13G (passive) | Nov 28, 2025 |
| Dapice Joshua J. | 1,227,590 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| Luo Patrick (Cheng) | 1,140,510 | 7.30% | 13G (passive) | Aug 8, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ASMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 4,977,089 | 24.44% | $136.77M | +471,698 | 8.30% |
| Farallon Capital Management LLC | 1,604,590 | 7.88% | $44.09M | +377,000 | 0.20% |
| Paradigm Biocapital Advisors LP | 1,553,748 | 7.63% | $42.70M | +888,497 | 0.80% |
| Commodore Capital LP | 1,415,000 | 6.95% | $38.88M | +415,000 | 2.32% |
| Ra Capital Management, L.P. | 1,020,410 | 5.01% | $28.04M | – | 0.24% |
| Jupiter Topco LLC | 849,309 | 4.17% | $23.37M | New | 0.01% |
| BlackRock, Inc. | 766,819 | 3.77% | $21.07M | +564,076 | 0.00% |
| Parkman Healthcare Partners LLC | 721,181 | 3.54% | $19.82M | +309,954 | 2.03% |
| Vanguard Capital Management LLC | 558,942 | 2.75% | $15.36M | +68,495 | 0.00% |
| Point72 Asset Management, L.P. | 460,593 | 2.26% | $12.66M | +116,488 | 0.01% |
| Seven Fleet Capital Management LP | 433,147 | 2.13% | $11.90M | +377,000 | 1.96% |
| Millennium Management LLC | 298,807 | 1.47% | $8.21M | +65,157 | 0.00% |
| Geode Capital Management, LLC | 280,424 | 1.38% | $7.71M | +147,453 | 0.00% |
| Schonfeld Strategic Advisors LLC | 242,153 | 1.19% | $6.65M | +121,653 | 0.02% |
| Ameriprise Financial Inc | 230,000 | 1.13% | $6.32M | New | 0.00% |
| Dv Equities, LLC | 226,415 | 1.11% | $6.22M | New | 0.89% |
| abrdn plc | 207,047 | 1.02% | $5.69M | New | 0.01% |
| Affinity Asset Advisors, LLC | 190,000 | 0.93% | $5.22M | New | 0.24% |
| B Group, Inc. | 175,706 | 0.86% | $4.83M | – | 2.27% |
| State Street Corp | 171,931 | 0.84% | $4.72M | +115,242 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 93 | 19M | 92.1% | 34 / 35 | 17 / 15 | 7M | 1M |
| Q1 2026 | 75 | 14M | 67.6% | 17 / 28 | 17 / 10 | 2M | 1M |
| Q4 2025 | 69 | 14M | 67.4% | 22 / 23 | 13 / 8 | 2M | 1M |
| Q3 2025 | 57 | 12M | 61.3% | 31 / 16 | 3 / 7 | 9M | 0M |
| Q2 2025 | 33 | 3M | 15.5% | 5 / 7 | 8 / 9 | 0M | 0M |
| Q1 2025 | 37 | 3M | 15.6% | 6 / 11 | 10 / 4 | 0M | 0M |
| Q4 2024 | 35 | 3M | 15.6% | 10 / 11 | 7 / 5 | 2M | 0M |
| Q3 2024 | 30 | 1M | 5.1% | 5 / 8 | 7 / 1 | 0M | 0M |
| Q2 2024 | 27 | 1M | 5.8% | 5 / 9 | 6 / 2 | 1M | 0M |
| Q1 2024 | 24 | 1M | 3.2% | 24 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ASMB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 413,284 | 2.03% | $11.36M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 244,994 | 1.20% | $6.73M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 133,292 | 0.65% | $3.66M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 107,386 | 0.53% | $2.70M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 89,271 | 0.44% | $2.45M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 58,396 | 0.29% | $1.62M | 0.00% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 40,982 | 0.20% | $1.03M | 0.09% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 33,135 | 0.16% | $910.55K | 0.06% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 23,781 | 0.12% | $597.14K | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 21,252 | 0.10% | $587.83K | 0.00% | May 31, 2026 |
| Small Cap Value Fund | 20,728 | 0.10% | $569.61K | 0.08% | Jun 30, 2026 |
| Master Small Cap Index Series | 18,425 | 0.09% | $506.32K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 16,917 | 0.08% | $467.92K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 13,750 | 0.07% | $377.85K | 0.02% | Jun 30, 2026 |
| Virtus Biotech Clinical Trials Etf | 13,537 | 0.07% | $339.91K | 0.73% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jason A. Okazaki | CEO and President, Director | 163,354 | 0.80% | Jun 5, 2026 |
| Jeanette M. Bjorkquist | PFO and PAO | 14,560 | 0.07% | Jun 18, 2026 |
| Nicole S. White | Chief Manufacturing Officer | 48,145 | 0.24% | Jun 5, 2026 |
| William E. Delaney IV | Chief Scientific Officer | 60,330 | 0.30% | Jun 5, 2026 |
| Anuj Gaggar | Chief Medical Officer | 42,688 | 0.21% | Jun 5, 2026 |
| Susan Mahony | Director | – | – | Jun 5, 2026 |
| Michael Houghton | Director | 3,202 | 0.02% | Jun 5, 2026 |
| Anthony E. Altig | Director | 8,000 | 0.04% | Jun 5, 2026 |
| Lisa Johnson-Pratt | Director | – | – | Jun 5, 2026 |
| Gina Consylman | Director | – | – | Jun 5, 2026 |
| John G. McHutchison | Director | 18,347 | 0.09% | Jun 5, 2026 |
| William R. Ringo | Director | 17,465 | 0.09% | Jun 9, 2025 |
| Gilead Sciences, Inc. | 10% owner | 4,977,089 | 24.44% | May 27, 2026 |
| Alexander Schornstein | 10% owner | 1,832,405 | 9.00% | Nov 26, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeanette M. Bjorkquist PFO and PAO | Jun 17, 2026 | Sale | −29 | $23.25 | $674 | 14,560 |
| Gilead Sciences, Inc. 10% owner | May 26, 2026 | Award | +471,698 | $26.50 | $12.50M | 4,977,089 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 30, 2026 | Sale | −312 | $26.65 | $8.31K | 11,105 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 30, 2026 | Sale | −16 | $27.49 | $440 | 11,089 |
| Nicole S. White Chief Manufacturing Officer | Mar 30, 2026 | Sale | −188 | $26.65 | $5.01K | 37,486 |
| Nicole S. White Chief Manufacturing Officer | Mar 30, 2026 | Sale | −9 | $27.49 | $247 | 37,477 |
| William E. Delaney IV Chief Scientific Officer | Mar 29, 2026 | Award | +14,000 | – | – | 60,330 |
| Anuj Gaggar Chief Medical Officer | Mar 29, 2026 | Award | +14,000 | – | – | 42,688 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 29, 2026 | Award | +3,500 | – | – | 14,589 |
| Nicole S. White Chief Manufacturing Officer | Mar 29, 2026 | Award | +14,000 | – | – | 48,145 |
| Jason A. Okazaki CEO and President, Director | Mar 29, 2026 | Award | +50,750 | – | – | 163,354 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 29, 2026 | Award | +6,500 | – | – | 11,417 |
| Nicole S. White Chief Manufacturing Officer | Mar 29, 2026 | Award | +26,000 | – | – | 37,674 |
| William E. Delaney IV Chief Scientific Officer | Mar 29, 2026 | Award | +26,000 | – | – | 45,642 |
| Jason A. Okazaki CEO and President, Director | Mar 29, 2026 | Award | +94,250 | – | – | 111,916 |
| Anuj Gaggar Chief Medical Officer | Mar 29, 2026 | Award | +26,000 | – | – | 28,000 |
| Gilead Sciences, Inc. 10% owner | Aug 8, 2025 | Buy | +2,295,920 | – | – | 4,505,391 |
| Jeanette M. Bjorkquist PFO and PAO | Jun 16, 2025 | Award | +300 | – | – | 5,097 |
| John G. McHutchison Director | Mar 31, 2025 | Sale | −757 | $9.85 | $7.46K | 18,347 |
| Jeanette M. Bjorkquist Principal Accounting Officer | Mar 31, 2025 | Sale | −180 | $9.85 | $1.77K | 4,617 |
| Nicole S. White Chief Manufacturing Officer | Mar 31, 2025 | Sale | −197 | $9.85 | $1.94K | 11,674 |
| Jason A. Okazaki CEO and President, Director | Mar 31, 2025 | Sale | −355 | $9.85 | $3.50K | 14,757 |
| Jeanette M. Bjorkquist Principal Accounting Officer | Mar 29, 2025 | Award | +1,655 | – | – | 4,797 |
| Michael Houghton Director | Dec 30, 2024 | Buy | +3,202 | $15.61 | $49.98K | 3,202 |
| Gilead Sciences, Inc. 10% owner | Dec 19, 2024 | Buy | +940,499 | $21.37 | $20.10M | 2,209,471 |
| Alexander Schornstein 10% owner | Nov 25, 2024 | Buy | +5,000 | $14.85 | $74.25K | 728,113 |
| Alexander Schornstein 10% owner | Nov 25, 2024 | Buy | +2,976 | $15.00 | $44.64K | 723,113 |
| Alexander Schornstein 10% owner | Nov 22, 2024 | Buy | +17,024 | $14.87 | $253.15K | 720,137 |
| Nicole S. White Chief Manufacturing Officer | Nov 18, 2024 | Sale | −40 | $16.29 | $652 | 11,871 |
| Alexander Schornstein 10% owner | Oct 8, 2024 | Buy | +10,000 | $14.58 | $145.80K | 703,113 |
| Nicole S. White Chief Manufacturing Officer | Oct 3, 2024 | Sale | −157 | $14.81 | $2.33K | 11,911 |
| Jason A. Okazaki CEO and President, Director | Oct 3, 2024 | Sale | −197 | $14.81 | $2.92K | 14,904 |
| Jason A. Okazaki CEO and President, Director | Aug 2, 2024 | Sale | −981 | $14.23 | $13.96K | 15,101 |
| Nicole S. White Chief Manufacturing Officer | Aug 2, 2024 | Sale | −785 | $14.23 | $11.17K | 12,068 |
| Alexander Schornstein 10% owner | Jul 5, 2024 | Buy | +4,438 | $12.52 | $55.56K | 693,113 |
| Alexander Schornstein 10% owner | Jul 3, 2024 | Buy | +4,562 | $12.29 | $56.07K | 688,675 |
| Gilead Sciences, Inc. 10% owner | Jun 17, 2024 | Buy | +179,500 | – | – | 1,268,972 |
| John G. McHutchison Director | May 23, 2024 | Sale | −2,117 | $14.93 | $31.61K | 19,104 |
| Jeanette M. Bjorkquist Principal Accounting Officer | May 23, 2024 | Sale | −24 | $14.93 | $358 | 3,142 |
| Jason A. Okazaki CEO and President, Director | May 23, 2024 | Sale | −549 | $14.93 | $8.20K | 16,082 |
| Nicole S. White Chief Manufacturing Officer | May 23, 2024 | Sale | −172 | $14.93 | $2.57K | 12,853 |
| Nicole S. White Chief Manufacturing Officer | Apr 30, 2024 | Sale | −1,255 | $12.71 | $15.95K | 13,025 |
| Jason A. Okazaki CEO and President, Director | Apr 30, 2024 | Sale | −1,569 | $12.71 | $19.94K | 16,423 |
| Nicole S. White Chief Manufacturing Officer | Apr 29, 2024 | Award | +3,333 | – | – | 14,280 |
| Jason A. Okazaki CEO and President, Director | Apr 29, 2024 | Award | +4,166 | – | – | 17,992 |
| William E. Delaney IV Chief Scientific Officer | Apr 29, 2024 | Award | +3,333 | – | – | 16,109 |
| Nicole S. White Chief Manufacturing Officer | Apr 1, 2024 | Sale | −197 | $13.07 | $2.57K | 10,947 |
| John G. McHutchison Director | Apr 1, 2024 | Sale | −1,206 | $13.07 | $15.76K | 21,221 |
| Jeanette M. Bjorkquist Principal Accounting Officer | Apr 1, 2024 | Sale | −114 | $13.07 | $1.49K | 3,166 |
| Jason A. Okazaki CEO and President, Director | Apr 1, 2024 | Sale | −354 | $13.07 | $4.63K | 13,826 |
| Jeanette M. Bjorkquist Principal Accounting Officer | Mar 29, 2024 | Award | +850 | – | – | 3,280 |
| Jason A. Okazaki CEO and President, Director | Mar 27, 2024 | Sale | −392 | $12.87 | $5.05K | 14,180 |
| Alexander Schornstein 10% owner | Jan 18, 2024 | Buy | +345,086 | $0.80 | $276.07K | 8,209,372 |
| Alexander Schornstein 10% owner | Jan 17, 2024 | Buy | +299,994 | $0.78 | $234.00K | 7,864,286 |
| Alexander Schornstein 10% owner | Nov 21, 2023 | Buy | +100,000 | $0.67 | $67.00K | 7,564,292 |
| Alexander Schornstein 10% owner | Nov 20, 2023 | Buy | +300,000 | $0.72 | $216.00K | 7,464,292 |
| Nicole S. White Chief Manufacturing Officer | Nov 17, 2023 | Sale | −477 | $0.69 | $329 | 93,774 |
| Jason A. Okazaki CEO and President, Director | Oct 3, 2023 | Sale | −2,363 | $0.80 | $1.89K | 174,923 |
| Nicole S. White Chief Manufacturing Officer | Oct 3, 2023 | Sale | −1,891 | $0.80 | $1.51K | 94,251 |
| William E. Delaney IV Chief Scientific Officer | Oct 3, 2023 | Sale | −1,891 | $0.80 | $1.51K | 150,853 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| A. Okazaki Jason Officer, Director | Oct 3, 2023 | 2,363 | $2.01K | Oct 3, 2023 | Restricted Stock Unit Release |
| E. Delaney William IV Officer | Oct 3, 2023 | 1,891 | $1.61K | Oct 3, 2023 | Restricted Stock Unit Release |
| Okazaki Jason Officer, Director | Aug 2, 2023 | 11,827 | $12.87K | Aug 2, 2023 | Restricted Stock Unit Release |
| E. Delaney William IV Officer | Aug 2, 2023 | 9,461 | $10.29K | Aug 2, 2023 | Restricted Stock Unit Release |
| E. Delaney William IV Officer | May 30, 2023 | 4,232 | $4.05K | May 30, 2023 | Restricted Stock Unit Release |
| G. McHutchison John Director | May 23, 2023 | 25,972 | $27.02K | May 23, 2023 | Restricted Stock Unit Release |
| E. Delaney William IV Officer | May 23, 2023 | 6,561 | $6.83K | May 23, 2023 | Restricted Stock Unit Release |
| Okazaki Jason Officer, Director | May 23, 2023 | 6,561 | $6.83K | May 23, 2023 | Restricted Stock Unit Release |